Fine chemical

 Celltrion Awarded up to $626 Million From the Department of Defense to Supply COVID-19 Point-of-Care (POC) Rapid Antigen Test Kits

Thursday, September 23, 2021 - 8:00am

Celltrion (KRX:068270) announced today that the Defense Logistics Agency (DLA) under the Department of Defense has awarded Celltrion USA, Inc., a subsidiary company of Celltrion, a procurement contract for its DiaTrustTM COVID-19 Ag Rapid Test.

Key Points: 
  • Celltrion (KRX:068270) announced today that the Defense Logistics Agency (DLA) under the Department of Defense has awarded Celltrion USA, Inc., a subsidiary company of Celltrion, a procurement contract for its DiaTrustTM COVID-19 Ag Rapid Test.
  • Celltrions supply capability for the contract volume is sufficiently supported by the large-scale production facility in Korea.
  • The test kits to be supplied through this contact are point-of-care tests (POCT) which can only be used in the presence of medical professionals.
  • Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs.

BioInnovation Institute Creation House program announces intake of four innovative early stage start-up companies

Thursday, September 23, 2021 - 8:00am

COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.
  • "BII's Creation House program is designed to support start-ups in their journey, and essentially increase the likelihood of success.
  • Creation House is for companies with a solid, initial business plan.
  • Its diverse team brings venture capital, pharma and business expertise together to help early stage companies accelerate to the next level.

BioInnovation Institute Creation House program announces intake of four innovative early stage start-up companies

Thursday, September 23, 2021 - 8:00am

COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ -- BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program. Creation House consists of a founder-friendly convertible loan of DKK 10M and 18 months incubation at BII with access to labs and office space, business development support, and BII partners. The program allows participants to meet and interact with BII's network of investors, industry partners, alumni and fellow entrepreneurs across its other programs, and is specifically designed to guide companies to a competitive international level and prepare teams for discussions with investors ahead of series A financing rounds.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.
  • "BII's Creation House program is designed to support start-ups in their journey, and essentially increase the likelihood of success.
  • Creation House is for companies with a solid, initial business plan.
  • Its diverse team brings venture capital, pharma and business expertise together to help early stage companies accelerate to the next level.

Zymo Research Receives CE IVD Mark for its EZ DNA Methylation-Lightning Kit

Thursday, September 23, 2021 - 7:15am

IRVINE, Calif., Sept. 23, 2021 /PRNewswire/ -- Today Zymo Research announced its EZ DNA Methylation-Lightning Kit™ has received the CE IVD Mark allowing the technology to be distributed within the European Union (EU) common market. Chemical treatment of DNA with bisulfite is the prerequisite for many methylation-based diagnostic assays. Clinical diagnostic and screening tests, particularly those for cancer and developmental diseases, are now utilizing methylation profiling of DNA to detect the presence of disease and guide treatment.

Key Points: 
  • IRVINE, Calif., Sept. 23, 2021 /PRNewswire/ --Today Zymo Research announced its EZ DNA Methylation-Lightning Kit has received the CE IVD Mark allowing the technology to be distributed within the European Union (EU) common market.
  • The EZ DNA Methylation-Lightning Kit features a ready-to-use conversion reagent, which streamlines the workflow for completion in a little over an hour.
  • The EZ DNA Methylation-Lightning Kit is one example of this philosophy," said Marc Van Eden, Zymo Research's Vice President of Business Development.
  • For more information about the EZ DNA Methylation-Lightning Kit, visit Zymo Research's website .

Zymo Research Receives CE IVD Mark for its EZ DNA Methylation-Lightning Kit

Thursday, September 23, 2021 - 6:31am

IRVINE, Calif., Sept. 22, 2021 /PRNewswire/ --Today Zymo Research announced its EZ DNA Methylation-Lightning Kit has received the CE IVD Mark allowing the technology to be distributed within the European Union (EU) common market.

Key Points: 
  • IRVINE, Calif., Sept. 22, 2021 /PRNewswire/ --Today Zymo Research announced its EZ DNA Methylation-Lightning Kit has received the CE IVD Mark allowing the technology to be distributed within the European Union (EU) common market.
  • The EZ DNA Methylation-Lightning Kit features a ready-to-use conversion reagent, which streamlines the workflow for completion in a little over an hour.
  • The EZ DNA Methylation-Lightning Kit is one example of this philosophy," said Marc Van Eden, Zymo Research's Vice President of Business Development.
  • For more information about the EZ DNA Methylation-Lightning Kit, visit Zymo Research's website .

BASF honored with the 2021 Safer Choice Partner of the Year award

Wednesday, September 22, 2021 - 10:07pm

BASF is among this year's 33 Safer Choice Partner of the Year Award winners and was honored for outstanding achievement in the design and manufacture of products with safer chemicals, which furthers outstanding or innovative source reduction.

Key Points: 
  • BASF is among this year's 33 Safer Choice Partner of the Year Award winners and was honored for outstanding achievement in the design and manufacture of products with safer chemicals, which furthers outstanding or innovative source reduction.
  • BASF wins 2021 Safer Choice Partner of the Year award for third consecutive time.
  • To qualify for the Safer Choice label, a product must meet EPA's Safer Choice Standard, which includes stringent human and environmental health criteria.
  • More information on the 2021 Safer Choice Partner of the Year award winners, and summaries of their accomplishments are available at: http://www.epa.gov/saferchoice/safer-choice-partner-year-awards .

Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021

Wednesday, September 22, 2021 - 10:00pm

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.

Key Points: 
  • The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.
  • Osmotica Pharmaceuticals plc (Nasdaq: OSMT), together with its subsidiaries, is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations.
  • In July 2020, the Company received regulatory approval from the U.S Food and Drug Administration for RVL-1201, or UPNEEQ (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults.
  • UPNEEQ was commercially launched September 2020 through RVL Pharmaceuticals, Inc., the Companys ophthalmic subsidiary, to a limited number of eye care professionals with commercialization operations expanded in 2021 among ophthalmology, optometry and oculoplastic specialties.

Boston Labs and Germfree Launch Mobile Cell and Gene Therapy (CGT) Manufacturing Platform

Wednesday, September 22, 2021 - 7:00pm

Clinical logistics and life science manufacturing leaders Boston Labs and Germfree Laboratories Inc. today announced their partnership to launch a new network of mobile CGT manufacturing facilities.

Key Points: 
  • Clinical logistics and life science manufacturing leaders Boston Labs and Germfree Laboratories Inc. today announced their partnership to launch a new network of mobile CGT manufacturing facilities.
  • The two companies are combining deep logistics, CGT manufacturing expertise and mobile cleanroom technology to deliver CGT point-of-care contract manufacturing services.
  • The CGT mobile manufacturing platform will launch in Boston, MA in the fourth quarter of 2021 and will scale to a network of global point-of-care mobile contract manufacturing centers.
  • Jon Mason, CEO of Boston Labs said: As the cell and gene therapy industry continues to grow, easier on-site access to cleanroom manufacturing facilities will likely be highly valued.

Zai Lab Holds Virtual Research and Development Day

Wednesday, September 22, 2021 - 5:22pm

SHANGHAI and SAN FRANCISCO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today held a Virtual R&D Day for analysts and investors to provide an in-depth look at its product portfolio and pipeline and its global operations.

Key Points: 
  • At the event, Zai Labs senior leadership provided deep dives into the companys marketed products and clinical candidates, including in-licensed assets to which Zai Lab has Greater China rights and compounds in its internal pipeline to which Zai Lab has global rights.
  • The presentations included discussions of product mechanisms of action, key preclinical and clinical data, differentiating features, and future development plans by both Zai Lab and its partners.
  • He also provided insight into Zai Labs internal research strategy and overviews of the companys internal pipeline products ZL-2309 (CDC7 inhibitor), ZL-1201 (CD47 inhibitor), ZL-2201 (DNA-PK), and ZL-1218 (Treg depleter).
  • Zai Lab has built exciting franchises of product candidates in autoimmune disorders and infectious diseases, with four truly differentiated assets, said Dr. Reinhart.

Unbounce Introduces the First Conversion Intelligence Platform, Ushering in a New Era of Digital Marketing for Small and Midsize Businesses

Wednesday, September 22, 2021 - 5:00pm

The Unbounce Conversion Intelligence Platform expands the companys offerings beyond landing pages and is designed to meet the needs of small and midsize businesses (SMBs).

Key Points: 
  • The Unbounce Conversion Intelligence Platform expands the companys offerings beyond landing pages and is designed to meet the needs of small and midsize businesses (SMBs).
  • The platform pairs a marketers intelligence with machine learning to increase the conversion rates of marketing campaigns at every touchpoint.
  • In a recent survey of marketers conducted on LinkedIn, Unbounce identified small business marketers' desire for more conversion growth as their top priority.
  • To answer this need, Unbounce created its new Conversion Intelligence Platform so SMBs can better compete against larger competitors and level up business growth.